Neuromyelitis Optica Spectrum Disorder (NMOSD) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

By Company 1.2.2. Analysis by Phase 1.2.3. By Molecule Type 1.2.4. By region 2. Disease Overview 2.1.1. Introduction 2.1.2. Classification 2.1.3. Symptoms 2.1.4. Causes 2.1.5. Diagnoses 2.1.6. Treatment 2.1.7. Epidemiology 3. Executive Summary 4. Market Dynamics 4.1. Drivers 4.2. Restraints 4.3. Opportunities 5. Pipeline Analysis/Outlook 5.1. Analysis by Company 5.2. Analysis by Phase 5.2.1. Phase of Development 5.2.1.1. Introduction 5.2.1.1.1. Drug Profiling • Drug Name • Generic Name • Synonyms • Company • Collaborator • Route of administration • Target • Mechanism of Action • Technology • Molecule type • CAS Number • Weight • Chemical Formula • IUPAC name • ATC code 5.2.1.1.2. Strategic Developments 5.2.1.1.3. Clinical trials 5.2.1.1.4. Clinical trial results 5.2.1.1.5. Patents 5.2.1.1.6. Technology 5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph) 5.3. By Molecule type 5.4. Analysis by Region 6. Company profiling 6.1. Roche Holdings. 6.1.1. Introduction 6.1.2. Financials 6.1.3. Products and Services 6.1.4. SWOT 6.2. Shire Plc 6.2.1. Introduction 6.2.2. Financials 6.2.3. Products and Services 6.2.4. SWOT 6.3. Nihon Pharmaceutical Co., Ltd 6.3.1. Introduction 6.3.2. Financials 6.3.3. Products and Services 6.3.4. SWOT 6.4. MedImmune LLC 6.4.1. Introduction 6.4.2. Financials 6.4.3. Products and Services 6.4.4. SWOT 6.5. RemeGen 6.5.1. Introduction 6.5.2. Financials 6.5.3. Products and Services 6.5.4. SWOT 6.6. Alexion Pharmaceuticals 6.6.1. Introduction 6.6.2. Financials 6.6.3. Products and Services 6.6.4. SWOT 6.7. Terumo BCT 6.7.1. Introduction 6.7.2. Financials 6.7.3. Products and Services 6.7.4. SWOT 6.8. Acorda Therapeutics 6.8.1. Introduction 6.8.2. Financials 6.8.3. Products and Services 6.8.4. SWOT 6.9. Abide Therapeutics, Inc. 6.9.1. Introduction 6.9.2. Financials 6.9.3. Products and Services 6.9.4. SWOT 6.10. Arrien Pharmaceuticals 6.10.1. Introduction 6.10.2. Financials 6.10.3. Products and Services 6.10.4. SWOT 6.11. NovelMed Inc. 6.11.1. Introduction 6.11.2. Financials 6.11.3. Products and Services 6.11.4. SWOT 6.12. TG Therapeutics, Inc. 6.12.1. Introduction 6.12.2. Financials 6.12.3. Products and Services 6.12.4. SWOT 6.13. 2-BBB Medicines BV 6.13.1. Introduction 6.13.2. Financials 6.13.3. Products and Services 6.13.4. SWOT 6.14. Apellis Pharmaceuticals Inc 6.14.1. Introduction 6.14.2. Financials 6.14.3. Products and Services 6.14.4. SWOT 6.15. Bionure Farma, S.L. 6.15.1. Introduction 6.15.2. Financials 6.15.3. Products and Services 6.15.4. SWOT 6.16. Hanall Biopharma 6.16.1. Introduction 6.16.2. Financials 6.16.3. Products and Services 6.16.4. SWOT 6.17. Vicore Pharma 6.17.1. Introduction 6.17.2. Financials 6.17.3. Products and Services 6.17.4. SWOT